Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy

被引:0
作者
Kestin, LL
Goldstein, NS
Lacerna, MD
Balasubramaniam, M
Martinez, AA
Rebner, M
Pettinga, J
Frazier, RC
Vicini, FA
机构
[1] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA
[2] William Beaumont Hosp, Dept Anat Pathol, Royal Oak, MI 48073 USA
[3] Albany Med Coll, Dept Radiat Oncol, Albany, NY 12208 USA
[4] William Beaumont Hosp, Dept Biostat, Royal Oak, MI 48072 USA
[5] William Beaumont Hosp, Dept Diagnost Radiol, Royal Oak, MI 48072 USA
[6] William Beaumont Hosp, Dept Surg, Royal Oak, MI 48072 USA
关键词
breast neoplasms; radiotherapy; intraductal carcinoma; mammary neoplasms; segmental mastectomy; combined modality therapy; breast-conserving therapy; mammography; lumpectomy;
D O I
10.1002/(SICI)1097-0142(20000201)88:3<596::AID-CNCR16>3.0.CO;2-N
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The authors reviewed their institution's experience treating patients with mammographically detected ductal carcinoma in situ (DCIS) of the breast with breast-conserving therapy (BCT) to determine 10-year rates of local control and survival and to identify factors associated with local recurrence. METHODS. From January 1980 to December 1993, 132 breasts in 130 patients were treated with BCT for mammographically detected DCIS at William Beaumont Hospital, Royal Oak, Michigan. All patients underwent an excisional biopsy, and 64% were reexcised. AU patients received postoperative whole-breast irradiation to a median dose of 45.0 Gray (Gy) (range: 43.1-56.0 Gy). One hundred twenty-four cases (94%) received a boost to the tumor bed for a median total dose of 60.4 Gy (range: 45.0-71.8 Gy). AU cases underwent complete pathologic review by one pathologist. The median follow-up was 7.0 years. RESULTS, Of the entire study group, 13 patients developed recurrence within the ipsilateral breast, for 5- and 10-year actuarial rates of 8.9% and 10.3%, respectively. Nine of the 13 recurrences (69%) occurred within or immediately adjacent to the lumpectomy cavity and were designated as true recurrences or marginal misses (TR/MM). Four patients (31%) had recurrence elsewhere in the breast. Ten of the 13 recurrences (77%) were invasive, whereas 3 (23%) were pure DCIS. Only 1 patient died of disease, corresponding to 5- and 10-year actuarial cause specific survival rates of 100% and 99.0%, respectively. Multiple clinical, pathologic, and treatment-related factors were analyzed for association with ipsilateral breast failure or TR/MM. In multivariate analysis, only the absence of pathologic calcifications was significantly associated with ipsilateral breast failure. When specifically analyzed for TR/MM, younger age at diagnosis, number of slides with DCIS, number of DCIS and cancerization of lobules (COL) foci within 5 mm of the margin, and the absence of pathologic calcifications demonstrated a statistically significant association. Close or positive margin status did nor significantly predict for either TR/MM (P = 0.14) or ipsilateral breast failure (P = 0.19). CONCLUSIONS. In patients with mammographically detected DCIS treated with BCT, adequate excision of all DCIS prior to RT can result in improved rates of local control. However, margin status may not adequately predict complete tumor extirpation. The volume of DCIS within 5 mm of the margin appears to be a more reliable surrogate for the adequacy of excision. In addition, young patient age and the absence of pathologic calcifications are independent risk factors for the development of local recurrence. (C) 2000 American Cnncer Society.
引用
收藏
页码:596 / 607
页数:12
相关论文
共 75 条
[1]  
AZZOPARDI JG, 1979, PROBLEMS BREAST PATH, P192
[2]  
BORNSTEIN BA, 1991, CANCER-AM CANCER SOC, V67, P7, DOI 10.1002/1097-0142(19910101)67:1<7::AID-CNCR2820670103>3.0.CO
[3]  
2-B
[4]  
Boyages J, 1999, CANCER, V85, P616, DOI 10.1002/(SICI)1097-0142(19990201)85:3<616::AID-CNCR12>3.3.CO
[5]  
2-Z
[6]  
COX DR, 1972, J R STAT SOC B, V34, P187
[7]   RADICAL SURGERY AND CONSERVATIVE TREATMENT OF DUCTAL CARCINOMA INSITU OF THE BREAST [J].
CUTULI, B ;
TEISSIER, E ;
PIAT, JM ;
JANSER, JC ;
RENAUD, R ;
RODIER, JF ;
JUNG, GM .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :649-654
[8]   Incidence of and treatment for ductal carcinoma in situ of the breast [J].
Ernster, VL ;
Barclay, J ;
Kerlikowske, K ;
Grady, D ;
Henderson, IC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (12) :913-918
[9]   ONE CENTURY OF MAMMARY-CARCINOMA IN-SITU - WHAT HAVE WE LEARNED [J].
FECHNER, RE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1993, 100 (06) :654-661
[10]  
FECHNER RE, 1971, CANCER, V28, P274, DOI 10.1002/1097-0142(197108)28:2<274::AID-CNCR2820280203>3.0.CO